Publications

Mease et al. assessed the comparative effectiveness of bimekizumab and risankizumab in patients with PsA over 52 weeks using a matching-adjusted indirect comparison (MAIC). The study included patients who were biologic disease-modifying anti-rheumatic drug (bDMARD) naïve or had a prior inadequate response or intolerance to tumour necrosis factor inhibitors (TNFi-IR).

The analysis found that bimekizumab demonstrated superior efficacy compared with risankizumab in achieving key clinical endpoints at Week 52 for both bDMARD-naïve patients and those with prior TNFi-IR. These results were obtained by matching individual patient data from bimekizumab trials with summary data from risankizumab trials, adjusting for baseline characteristics to ensure comparability.